Search
Pomegranate
go.drugbank.com/drugs/DB14317InvestigationalPomegranate is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Rexin G
go.drugbank.com/drugs/DB16450InvestigationalIt is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry. … Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene.
AT3022
go.drugbank.com/drugs/DB05172ExperimentalAT3022, the Altea Therapeutics’s fentanyl citrate transdermal patch designed to provide safe and rapid management of moderate to severe chronic pain.
Pirlindole
go.drugbank.com/drugs/DB09244ExperimentalThis drug is classified as a reversible inhibitor of monoamine oxidase A enzyme (also known as a RIMA drug). It was developed and is currently used as an antidepressant in Russia. … Its chemical structure is similar to metralindole, and it also shares pharmacological properties with this drug.
Synonyms: 2,3,3a,4,5,6-Hexahydro-8-methyl-1H-pyrazino(3,2,1-jk)carbazoleCategories: Serotonin Receptor Antagonists, Serotonin 5-HT1 Receptor AntagonistsPRO-542
go.drugbank.com/drugs/DB05793InvestigationalPRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. … PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.
Linsitinib
go.drugbank.com/drugs/DB06075InvestigationalAn orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. … IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.
Asvasiran
go.drugbank.com/drugs/DB05638InvestigationalAsvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.
Osanetant
go.drugbank.com/drugs/DB04872InvestigationalDeveloped by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System … In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant.
105AD7
go.drugbank.com/drugs/DB05113Investigational105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in